DJIA 17,810.06 91.06 0.51%
NASDAQ 4,712.97 11.10 0.24%
S&P 500 2,063.50 10.75 0.52%
market minute promo

1.25 0.04 (3.31%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NAVB $1.25 3.31%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.25
Previous Close $1.21
Daily Range $1.20 - $1.27
52-Week Range $0.97 - $2.25
Market Cap $188.4M
P/E Ratio -4.17
Dividend (Yield) $0.00 (0.0%)
Volume 1,182,511
Average Daily Volume 1,078,990
Current FY EPS -$0.21

Sector

Healthcare

Industry

Healthcare Information Services

Navidea Biopharmaceuticals, Inc. (NAVB) Description

Neoprobe Corporation is a biomedical company which is engaged in the development and commercialization of innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of physicians. Website: http://www.navidea.com/

News & Commentary Rss Feed

This Week in Biotech: Actions Speak Louder Than Words

Regulatory actions provided the impetus to big moves for these five biotech stocks.

European Commission Approves Navidea's Sentinel Lymph Node Detection Agent Lymphoseek

Navidea Biopharmaceuticals (NAVB) Jumps: Stock Up 7.8% - Tale of the Tape

Sector Update: Health Care Stocks Generally Higher Pre-Bell

Sector Update: Health Care

Navidea Receives $1.1M PDUFA Filing Fee Refund For Award Of Orphan Drug Status; Platinum Partners Re

Navidea Receives $1.1M PDUFA Filing Fee Refund For Award Of Orphan Drug Status; Platinum Partners Reaffirms Commitment To Line Of Credit

Navidea Biopharmaceuticals, Inc's (NAVB) CEO Rick Gonzalez on Q3 2014 Results - Earnings Call Transc

Navidea Biopharmaceuticals, Inc's (NAVB) CEO Rick Gonzalez on Q3 2014 Results - Earnings Call Transcript

Navidea Biopharmaceuticals Q3: What's Going On With Lymphoseek?

Navidea Biopharmaceuticals (NAVB) Q3 2014 Results - Earnings Call Webcast

Should You Buy Navidea Biopharmaceuticals?

Sector Update: Health Care Stocks Near Break-Even Marks; Navidea Wins Orphan Drug Designation for He

Sector Update: Health Care Stocks Near Break-Even Marks; Navidea Wins Orphan Drug Designation for Head, Neck Cancer Medication

See More NAVB News...

NAVB's Top Competitors

NAVB $1.25 (3.31%)
Current stock: NAVB
$0.00 (0.00%)
Current stock:
MDT $72.49 (0.57%)
Current stock: MDT
COV $98.44 (0.54%)
Current stock: COV